Programs
Powered by the invention of our revolutionary new class of medicines, we are developing first-in-class treatments for cancers with high unmet medical needs.

We are focused on developing three categories of Bicycles against our oncology targets:

Bicycle Toxin ConjugatesBicycle Targeted Innate Immune ActivatorsBicycle T-Cell Modulators

Programs

Powered by the invention of our revolutionary new class of medicines, we are developing first-in-class treatments for cancers with high unmet medical needs.

We are focused on developing three categories of Bicycles against our oncology targets:

Bicycle Toxin ConjugatesBicycle Targeted Innate Immune ActivatorsBicycle T-Cell Modulators

We are rapidly advancing our robust pipeline of Bicycles, focusing on targeted cytotoxics (Bicycle Toxin Conjugates), targeted innate immune activators and T-cell modulators.

Our lead molecule, BT1718, is a Bicycle Toxin Conjugate being developed to target tumours of high unmet need. Cancer Research UK’s Centre for Drug Development (CDD) is sponsoring a Phase I/IIa study of BT1718.

Bicycle Toxin Conjugates

Discovery
Pre-clinical
Clinical
MT1 Program (BT1718)
Pre-clinical
EphA2 Program
Pre-clinical
Nectin-4 Program
Discovery

Bicycle Targeted Innate Immune Activators

Discovery
Pre-clinical
Clinical
TLR Agonist, STING Programs
Discovery

Bicycle T-Cell Modulators

Discovery
Pre-clinical
Clinical
CD137 Program
Discovery